BioNova Announces FDA Clearance of IND Application for BN104 for the Treatment of Acute Leukemia
SHANGHAI, China, Sep. 21, 2023 - BioNova Pharmaceuticals Limited (BioNova) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BN104 for the treatment of relapsed/refractory (R/R) acute leukemia.
